Plus Therapeutics, Inc.
PSTV · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.02 | -0.01 | -0.00 | -0.02 |
| FCF Yield | -3.51% | -34.49% | -44.62% | -13.51% |
| EV / EBITDA | -13.88 | 2.77 | -0.30 | -3.41 |
| Quality | ||||
| ROIC | -88.32% | -50.20% | -230.06% | 69.87% |
| Gross Margin | 93.84% | 93.81% | 82.91% | 83.57% |
| Cash Conversion Ratio | 0.58 | -1.13 | 0.35 | 0.31 |
| Growth | ||||
| Revenue 3-Year CAGR | 11.92% | 27.19% | 92.48% | 196.25% |
| Free Cash Flow Growth | 55.64% | 5.99% | -405.32% | 66.92% |
| Safety | ||||
| Net Debt / EBITDA | 3.06 | -0.42 | 0.73 | -0.91 |
| Interest Coverage | 0.00 | 0.00 | -0.94 | -68.42 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -6,588.66 | -4,585.52 | -3,638.86 |